author-photo

Lori A. Kunkel

Novartis

9

Papers

1880

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

2015 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (6)
Open-Label Evaluation of ECG in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Ibrutinib Monotherapy

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

2012 Blood
Show All
- Source
- Cite
- Save
Citations (40)
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1602)
High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993

1999
Show All
- Source
- Cite
- Save
Citations (0)